Učitavanje...
Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England
PURPOSE: The aim of this study was to compare the cost-effectiveness of cabozantinib with the standard of care in England in adult patients with advanced renal cell carcinoma (aRCC), following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy. METHODS: We developed a partiti...
Spremljeno u:
| Izdano u: | Clinicoecon Outcomes Res |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5922245/ https://ncbi.nlm.nih.gov/pubmed/29719414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S159833 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|